Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 8,018 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
Prerandomization run-in periods are being used to select or exclude patients in an increasing number of clinical trials, but the implications of run-in periods for interpreting the results of clinical trials and applying these results in clinical practice have not been systematically examined.
Why it matters
This analysis explains that when trials use a run-in period to exclude people who do not tolerate or respond to a drug, the reported results are valid but apply only to a subgroup of patients who cannot be easily identified in practice. Such results can overestimate benefits and underestimate risks of treatment, which matters for how Alzheimer drug trial findings should be applied to patients.
-
Design review and abstraction of medical records and computerized data bases from 5986 members, aged 65 years and older, of a large health maintenance organization in northern California.
-
45/100
Applications of the random fluid-based probabilistic atlas include the transfer of multisubject 3D functional, vascular, and histologic maps onto a single anatomic template, the mapping of 3D atlases onto the scans of new subjects, and the rapid detection, quantification, and mapping of local shape changes in 3D medical images in disease and during normal or abnormal growth and development.
Why it matters
This paper describes a computational method for building a probabilistic atlas of the brain surface to detect subtle deviations from normal cortical anatomy. It is a technical imaging tool and does not test any treatment, cure, or prevention for Alzheimer's disease.
-
Dementia adversely affects driving performance even in its mild stages, although some persons with DAT seem to drive safely for some time after disease onset.
-
The cognitive assessment protocol of the Alzheimer's Disease Cooperative Study (ADCS) was designed to evaluate the reliability and validity of cognitive assessment measures that might be valuable additions to the Alzheimer's Disease Assessment Scale (ADAS) or other concise batteries used in antidementia drug trials.
Why it matters
Tested five cognitive tests in people with mild to moderate Alzheimer's disease and cognitively normal older adults over 1 year, looking for additions to the Alzheimer's Disease Assessment Scale (ADAS) used in drug trials. A digit cancellation task was reliable across dementia severity and word learning with delayed recall was impaired even in mild Alzheimer's, while facial recognition and praxis tasks were not related to dementia severity.
-
Incurably ill patients often receive nonpalliative interventions at the end of life.
-
This study aimed at investigating the clinical usefulness of the Mental Deterioration Battery (MDB) in the neuropsychological diagnosis and characterization of the dementia syndrome.
Why it matters
The Mental Deterioration Battery was confirmed as reliable for distinguishing normal from demented patients and for characterizing patterns of cognitive impairment. It is a neuropsychological diagnostic tool, not a treatment or cure.
-
To evaluate the presence and distribution of central nervous system infection by human immunodeficiency virus type 1 (HIV-1), we used immunohistochemical methods to map the HIV-1 p24 core protein in the brains of 55 autopsied patients with acquired immunodeficiency syndrome (AIDS).
Why it matters
This study mapped HIV-1 virus protein in the brains of 55 autopsied AIDS patients and related the amount of infection to the severity of AIDS dementia complex. It describes how HIV infects brain immune cells rather than neurons directly, which may inform understanding of dementia caused by HIV but does not address Alzheimer's disease treatment or prevention.
-
We report the neuropathological findings in 32 patients, aged 46-86 years, with dementia lacking distinctive histopathology.
Why it matters
This clinicopathological evaluation of 32 patients with dementia lacking distinctive histopathology found frontal or temporopolar atrophy in 97% of cases, with hippocampus and subcortical structures relatively spared in most cases. The findings further demonstrate the epidemiological and neuropathological heterogeneity of these dementias.
-
Data on 1888 patients seen at Alzheimer's Disease Diagnostic and Treatment Centers in California were used to examine possible differences in Mini-Mental State Examination (MMSE) results for different racial-ethnic groups.
Why it matters
This study found that Mini-Mental State Examination scores for Black and Hispanic patients appeared to underestimate their cognitive capabilities relative to white patients, even after accounting for education, occupation, age, and sex. This concerns how a screening test performs across racial-ethnic groups, not treatment, cure, or prevention.
-
Several recent autopsy studies suggest that senile dementia of Lewy body type (SDLT) may be the second most common neuropathologic cause of dementia in the elderly, accounting for 7 to 30% of all cases.
Why it matters
Clinical criteria for diagnosing senile dementia of Lewy body type during life showed high specificity but only moderate sensitivity, and accuracy depended on the clinician's experience. This may help doctors identify some patients with this dementia type more accurately, but it does not offer a treatment, cure, or prevention.
-
45/100
We analyzed the number and nature of falls in a nursing home for elderly patients with dementia.
-
Using a structured instrument, 325 elderly patients admitted to a general hospital for an acute medical problem were evaluated daily in order to detect symptoms of delirium.
-
We studied whether Mini-Mental State Examination (MMSE) norms for detecting dementia in elderly outpatients vary according to educational attainment.
Why it matters
This study examined whether the MMSE's accuracy for detecting dementia in elderly outpatients varies with educational attainment across 109 Alzheimer's patients and 100 controls. It is about how education affects a screening test's performance, not about treating, curing or preventing Alzheimer's disease.
-
The usefulness of the Mini-Mental State Examination (MMSE) as a screening test for identifying cognitive impairment in patients with multiple sclerosis (MS) has been questioned because many patients who score above the suggested cutoff score of 24 exhibit severe focal or global cognitive deficits.
Why it matters
This study evaluated the Mini-Mental State Examination as a screening test in 85 patients with multiple sclerosis, not Alzheimer's disease. It found the test was not sensitive enough to identify dementia in these patients and does not address treating, curing, or preventing Alzheimer's disease.
-
Thirty cases of diffuse Lewy body disease (DLBD) have been reported, primarily by neuropathologists, but an associated clinical syndrome has not been clearly defined.
-
A significant proportion of patients with presenile dementia due to primary cerebral atrophy do not have Alzheimer's disease.
Why it matters
This study describes seven patients with dementia of frontal lobe type, a non-Alzheimer dementia with social misconduct, personality change, and frontal lobe test abnormalities, and compares them with Alzheimer patients. It characterizes a different form of dementia and does not test any treatment, cure, or prevention for Alzheimer's disease.
-
Behavioral problems are thought to be pervasive and devastating to patients with dementia of the Alzheimer's type and their families.
-
Patchy subcortical foci of increased signal intensity are frequently identified on magnetic resonance imaging (MRI) in the elderly.
Why it matters
Small areas of changed signal on MRI in the elderly became more common and more severe with age and were linked to prior cerebrovascular disease and hypertension. Apart from cerebrovascular disease, these incidental lesions were not associated with any particular clinical condition, including dementia.
-
The suprachiasmatic nucleus (SCN) is considered to be the endogenous clock of the brain, essential for the ovulation cycle and the temporal organization of sleep-wake patterns, among other things.
Why it matters
This morphometric study of the human brain found that the suprachiasmatic nucleus decreased in volume and cell number in old age, with the change especially pronounced in patients with senile dementia of the Alzheimer type. It suggests a structural defect underlying disturbed biological rhythms in aging and this dementia, not a treatment, cure, or prevention.
-
The authors analyze 133 cases of organic mental disorders (OMDs) from a total of 771 patients who were referred for psychiatric consultation from a general hospital.
-
Patients with dementia, schizophrenia and depression were tested with analogous auditory and visual event-related potential (ERP) paradigms designed to elicit a large P3.
Why it matters
This study found that P3 brain-wave abnormalities in dementia were not specific and were not sensitive enough to diagnose individuals. It reports no diagnostic test reliable enough for individual use and does not address treatment, cure, or prevention.
-
44/100
Fifty-three sources were included.
Why it matters
This review of GLP-1-based therapies reports histological improvement in a liver condition and reduced kidney outcomes in people with type 2 diabetes and chronic kidney disease. It reports no findings about treating, curing or preventing Alzheimer's disease.
-
Medicare Part D drug spending was substantial, increasing with dual-eligibility duration: $8732-$9107 among beneficiaries with full-year dual eligibility and exceeding $11 500 among those with 5+ chronic conditions.
Why it matters
This cross-sectional analysis of 1,372,696 community-dwelling Medicare fee-for-service beneficiaries with Alzheimer's disease and related dementias found substantial Medicare Part D drug spending that increased with dual-eligibility duration, exceeding $11,500 among those with five or more chronic conditions. It describes drug spending and out-of-pocket cost variation rather than any treatment, cure, or prevention.
-
We found comparable associations between dementia and PRS when comparing a C+T method with only 15 SNPs and PRS derived from Bayesian models that include > 800,000 SNPs (HR 5e‐08 = 1.18, 95% CI: 1.08–1.28; HR CSx = 1.17, 95% CI: 1.07−1.27).
Why it matters
This study found that a polygenic risk score using only 15 genetic variants performed comparably to scores using over 800,000 variants in predicting incident dementia across diverse ethnic groups. It suggests that simpler genetic risk scores may be useful, but it does not test a treatment or prevention.
From across this topic
10 of the 7,967 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Palliative care for end-stage dementia: a discussion of the implications for education of health care professionals
- Mental and physical activities delay cognitive decline in older persons with dementia
- The significance of a dementia diagnosis from the perspective of the family caregivers: a qualitative study
- Telehealth Use by Home Health Agencies Before, During, and After COVID-19
- Socioeconomic disparities and nutritional aging: how food insecurity and financial hardship accelerate health decline in older adults
- Apathy in Dementia: A Pilot Study Providing Insights from Neuropsychiatric and Radiological Perspectives
- A comparison of machine learning methods for survival analysis of high-dimensional clinical data for dementia prediction
- The prevalence and causes of dementia in people under the age of 65 years
- Predicting the rate of cognitive decline in aging and early Alzheimer disease
- Intrinsic capacity and its associations with incident dependence and mortality in 10/66 Dementia Research Group studies in Latin America, India, and China: A population-based cohort study